Patents by Inventor Robert Hugh Bradbury

Robert Hugh Bradbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds—643
    Patent number: 8258140
    Abstract: The invention concerns bicyclic compounds of Formula I wherein , R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 4, 2012
    Assignee: Astrazeneca AB
    Inventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
  • Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
    Patent number: 8003649
    Abstract: The invention concerns bicyclic compounds of Formula I wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 23, 2011
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Neil James Hales
  • CHEMICAL COMPOUNDS 751
    Publication number: 20100292222
    Abstract: The invention concerns bicyclic compounds of Formula (I) wherein, R1, R2, R3, R4, R5, X1, X2, Y, k, m, n and p are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: May 10, 2010
    Publication date: November 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow
  • 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
    Patent number: 7820683
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Bernard Christophe Barlaam, Richard Ducray
  • CHEMICAL COMPOUNDS - 643
    Publication number: 20100267699
    Abstract: The invention concerns bicyclic compounds of Formula I wherein , R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: February 9, 2010
    Publication date: October 21, 2010
    Inventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
  • 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
    Publication number: 20100152442
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: February 16, 2010
    Publication date: June 17, 2010
    Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
  • INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS
    Publication number: 20100029696
    Abstract: A quinazoline derivative of the Formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    Type: Application
    Filed: February 28, 2006
    Publication date: February 4, 2010
    Inventor: Robert Hugh Bradbury
  • BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
    Publication number: 20100016279
    Abstract: The invention concerns bicyclic compounds of Formula I wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 21, 2010
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Neil James Hales
  • Quinazoline derivatives
    Patent number: 7625908
    Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Grant
    Filed: November 11, 2004
    Date of Patent: December 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Laurent Francois Andre Hennequin, Robert Hugh Bradbury, Jason Grant Kettle
  • QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS
    Publication number: 20090239861
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: September 14, 2006
    Publication date: September 24, 2009
    Inventor: Robert Hugh Bradbury
  • INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS
    Publication number: 20090137615
    Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: February 28, 2006
    Publication date: May 28, 2009
    Inventor: Robert Hugh Bradbury
  • 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20090048251
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: September 14, 2006
    Publication date: February 19, 2009
    Inventors: Robert Hugh Bradbury, Bernard Christophe Barlaam, Richard Ducray
  • QUINAZOLINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE
    Publication number: 20090029968
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: November 29, 2006
    Publication date: January 29, 2009
    Inventors: Bernard Christophe Barlaam, Robert Hugh Bradbury, Richard Ducray
  • Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase
    Publication number: 20090023759
    Abstract: A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
    Type: Application
    Filed: April 27, 2006
    Publication date: January 22, 2009
    Inventor: Robert Hugh Bradbury
  • 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
    Publication number: 20080269487
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: June 26, 2008
    Publication date: October 30, 2008
    Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
  • Quinazoline Derivatives
    Publication number: 20080096881
    Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 15, 2004
    Publication date: April 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Laurent Francois Andre Hennequin, Bernard Christophe Barlaam, Robert Hugh Bradbury
  • Quinazoline derivatives
    Patent number: 7148230
    Abstract: The invention concerns quinazoline derivatives of Formula I wherein R1 and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: December 12, 2006
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Jason Grant Kettle, James McCabe, Andrew Turner, Laurent Francois Andre Hennequin
  • 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
    Patent number: 7067522
    Abstract: Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: June 27, 2006
    Assignee: AstraZeneca AB
    Inventors: Elizabeth Janet Pease, Emma Jane Williams, Robert Hugh Bradbury, Stuart Eric Pearson
  • 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
    Patent number: 6838464
    Abstract: Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: January 4, 2005
    Assignee: AstraZeneca AB
    Inventors: Elizabeth Janet Pease, Emma Jane Williams, Robert Hugh Bradbury, Stuart Eric Pearson
  • Pyrimidine compounds
    Patent number: 6710052
    Abstract: Pyrimidine derivatives of the formula (I) wherein: one of Q1 and Q2 or both of Q1 and Q2 is substituted on a ring carbon by one substituent of the formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the —NH— link]; wherein Q1, Q2, G, R1, X, Y1, Y2, Z, n and m are as described within; and pharmaceutically acceptable salts and in vivo hydrolyzable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: March 23, 2004
    Assignee: AstraZeneca
    Inventors: Elizabeth Janet Pease, Gloria Anne Breault, Robert Hugh Bradbury